The Monash IVF (ASX:MVF) share price is gaining 6% today. Here's why

The company appears to be benefiting from Victoria lifting a ban on IVF treatments.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A couple smile as they look at a pregnancy test.

Image source: Getty Images

Key points

  • The Monash IVF share price has lifted nearly 6% today
  • It comes after COVID-19 IVF restrictions were lifted in Victoria
  • The company will resume IVF services next week

The Monash IVF Group Ltd (ASX: MVF) share price is rising today amid the lifting of a COVID-19-related suspension on IVF treatments.

The fertility services company's shares are trading at $1.052 in afternoon trade, up 5.73%.

Let's take a look at what may be impacting the company today.

Victoria IVF ban lifted

Investors appear to be reacting positively to news the company will be able to recommence fertility services. The Victorian State Government lifted a temporary ban on IVF procedures today.

The order had originally slated IVF procedures to remain suspended until 12 April due to COVID-19 restrictions on non-urgent surgeries.

Today, however, the government reversed this decision which will enable IVF procedures to recommence. Monash IVF says it will recommence its IVF services by 26 January.

An online petition calling for a reversal of the suspension of fertility treatments across Victoria gained 140.000 signatures, 7News reported.

In a statement released to the ASX, Monash IVF stated:

Monash IVF is pleased IVF procedures will recommence and the company is focussed on informing patients of their options to recommence their treatment and ensure sufficient workforce and resources are in place to meet demand.

The company also remains focussed on maintaining appropriate measures and protocols in place to protect the health and safety of the company's patients, employees and specialists.

Monash IVF shares have seen consistent gains in the past year. In November, the company released its financial results for FY 2021, which showed adjusted net profit after tax soared 61.5% compared to the previous financial year.

Monash IVF share price snapshot

The Monash IVF share price has soared around 42% in the past year but is flat this year to date.

In contrast, the S&P/ASX 200 Index (ASX: XJO) has returned about 8% in the past 12 months.

Monash IVF has a market capitalisation of about $409 million based on its current share price.

Motley Fool contributor Monica O'Shea has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Two happy pharmacists standing together in a pharmacy.
Healthcare Shares

Why Clarity Pharmaceuticals shares just fell 5% on today's announcement

Investors are balancing Clarity's long-term potential against near-term uncertainty.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

Still down 40%, are Pro Medicus shares primed to break out?

Two major US contract wins in as many weeks could mark a turning point in sentiment.

Read more »

Happy healthcare workers in a lab.
Healthcare Shares

Telix share price leaping higher today on $3 billion US news

Investors are snapping up Telix shares on Monday following big US news.

Read more »

Four smiling young medics with arms crossed stand outside a hospital.
Healthcare Shares

Pro Medicus locks in 5-year, $37m Northwestern Medicine contract renewal

Pro Medicus has renewed its major contract with Northwestern Medicine, locking in higher fees and strengthened client ties for the…

Read more »

Rising healthcare ASX share price represented by doctor giving thumbs up
Healthcare Shares

Telix Pharmaceuticals announces US$40m Regeneron radiopharma deal

Telix Pharmaceuticals has announced a US$40m strategic collaboration with Regeneron for innovative radiopharmaceutical cancer therapies.

Read more »

Two health workers taking a break.
Healthcare Shares

It could be time to buy-low on this ASX small-cap stock according to brokers

This ASX healthcare stock keeps attracting positive ratings, with one broker now tipping a 268% rise.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Broker sees 26% upside in ASX healthcare share behind Chemist Warehouse

Morgans has just upgraded its rating on this ASX healthcare stock due to ongoing share price weakness.

Read more »

Woman using a pen on a digital stock market chart in an office.
Healthcare Shares

Why this ASX healthcare stock is surging while the market sinks on Middle East fears

Avita shares surge as a US government contract boosts sentiment again

Read more »